Spyre Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $0.0 | $0.9 | $2.3 | $18.7 |
| Operating income | -$209.6 | -$208.6 | -$242.3 | -$84.8 | -$65.6 |
| Net income | -$155.2 | -$208.0 | -$338.8 | -$83.8 | -$65.8 |
| Cash Flow Statement | |||||
| Free cash flow | — | -$157.4 | -$99.9 | -$80.2 | -$54.3 |
| Dividends | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Shares outstanding 88.2M · Free float 64.8%
Annual filing data through FY ended December 31, 2025; float as of October 1, 2026.